Albuminuria

There are 351 papers on albuminuria in aging research: 16 trials and 150 observational studies in people, 53 in animals, 126 reviews. The newest story, Nov 13, 2026: “Chronic kidney disease linked to higher stroke risk”.

Biomarker

351 papers study it315 more mention it144 findings

MeSH

109 new papers in 30 daysSee all 666 papers on albuminuria

“moderate (30-299 mg/g) or severe (≥300 mg/g) albuminuria increased AAA risk by 33% (HR 1.33; 95% CI 1.23-1.44) and 49% (HR 1.49; 1.28-1.73), respectively.”
Association of albuminuria and changes in albuminuria with the risk of abdominal aortic aneurysmAtherosclerosis2026doi:10.1016/j.atherosclerosis.2026.120692
  • Human trial16
  • Humans150
  • Animals53
  • In silico1

Interventions

44

GLP-1 receptor agonists

downin humans5downin reviews2

7 studies
  1. GLP-1 receptor agonists decrease albuminuria in humans.

    “nephroprotection with reduction of albuminuria and slowing of eGFR decline”

    Reviewkidney

    GLP-1 Receptor Agonists in Urology and Andrology: Indications, Opportunities and Clinically Relevant Adverse Effects

    Zentralblatt fur Chirurgie

  2. GLP-1 receptor agonists decrease albuminuria in humans (diabetic kidney disease).

    “Randomized clinical trials and real-life analyses have demonstrated reductions in albuminuria and slowing of glomerular filtration rate (GFR) decline.”

    Reviewdiabetic kidney diseasekidney

    Renal Effects of Glucagon-like Peptide-1 Receptor Agonists in Diabetic Kidney Disease: A Narrative Review of Mechanisms and Clinical Evidence

    Medicina (Kaunas, Lithuania)

  3. GLP-1 receptor agonists decrease albuminuria.

    “leading to reduced albuminuria and a slower decline in renal function”

    Reviewproposed mechanism: modulation of proximal tubular sodium reabsorption and tubuloglomerular feedbackkidney

    GLP-1RA pharmacokinetics and clinical effects: focus on cardiac, vascular, and glomerular structures

    Expert opinion on drug metabolism & toxicology

  4. GLP-1 receptor agonists decrease albuminuria in humans.

    “Glucagon-like peptide-1 receptor agonists demonstrate similar but less uniform effects, driven largely by reductions in albuminuria.”

    Review

    Primary Prevention of CKD for Heart and Kidney Health: Ready for Primetime?

    Clinical journal of the American Society of Nephrology : CJASN

  5. GLP-1 receptor agonists decrease albuminuria in patients with type 2 diabetes mellitus.

    “underscoring their role in reducing albuminuria and preserving renal function”

    Reviewin patients with type 2 diabetes mellitus

    Glucagon-like Peptide Receptor Agonists and Kidney Outcomes in the Era of Personalized Medicine: Focus on Albuminuria

    Journal of personalized medicine

  6. GLP-1 receptor agonists decrease albuminuria in patients with diabetic chronic kidney disease, per cited trials.

    “Clinical trials such as SUSTAIN-6, REWIND, and FLOW provide evidence of GLP-1 receptor agonists reducing albuminuria and attenuating estimated glomerular filtration rate decline in patients with diabetic chronic kidney disease.”

    Reviewin patients with diabetic chronic kidney disease, per cited trialskidney

    Glucagon-Like Peptide-1 Receptor Agonists in Chronic Kidney Disease: Mechanisms and Clinical Perspectives

    Kidney medicine

  7. GLP-1 receptor agonists decrease albuminuria.

    “GLP-1RAs have been shown to reduce albuminuria”

    Reviewkidney

    Glucagon-like peptide-1 receptor agonists and kidney outcomes

    Journal of diabetes

More on GLP-1 receptor agonists

SGLT2 inhibitors

downin humans3

3 studies
  1. SGLT2 inhibitors are linked with lower albuminuria in humans (-35.6% at 1 year and -43.5% at 2 years).

    “UACR declined significantly (-35.6% at 1 year and -43.5% at 2 years; p = 0.004)”

    Humans1 and 2 years

    Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real-World National Study

    Diabetes, obesity & metabolism

  2. SGLT2 inhibitors decrease albuminuria in humans.

    “SGLT2i consistently reduce albuminuria”

    Reviewkidney

    Clinical Evidence of Kidney Protection Exerted by SGLT2 Inhibitors

    Handbook of experimental pharmacology

  3. SGLT2 inhibitors decrease albuminuria in humans (without CKD at baseline).

    “sodium-glucose cotransporter 2 inhibitors consistently attenuate eGFR decline and reduce incident or progressive albuminuria, including among participants without CKD at baseline”

    Reviewwithout CKD at baseline

    Primary Prevention of CKD for Heart and Kidney Health: Ready for Primetime?

    Clinical journal of the American Society of Nephrology : CJASN

More on SGLT2 inhibitors

Tirzepatide

downin humans2downin reviews1

3 studies
  1. Tirzepatide decreases albuminuria in humans (compared with insulin glargine).

    “Tirzepatide demonstrated consistent albuminuria reductions and attenuation of eGFR decline compared with insulin glargine.”

    Reviewcompared with insulin glarginekidney

    Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review

    Diabetes therapy : research, treatment and education of diabetes and related disorders

  2. Tirzepatide decreases albuminuria.

    “its protective renal effects, especially on decreasing albuminuria and eGFR slopes”

    Reviewkidney

    Comparative safety and side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

  3. Tirzepatide decreases albuminuria in humans (post hoc analysis of SURPASS-4 versus insulin glargine).

    “tirzepatide decreased albuminuria and total estimated glomerular filtration rate (eGFR) slopes”

    Reviewpost hoc analysis of SURPASS-4 versus insulin glarginekidney

    Tirzepatide and prevention of chronic kidney disease

    Clinical kidney journal

More on Tirzepatide

Dapagliflozin

downin killifish2

2 studies
  1. Dapagliflozin decreases albuminuria in killifish (age-related kidney aging).

    “reduced albuminuria”

    Animalsage-related kidney agingkidney

    Sodium-glucose co-transporter 2 inhibition improves age-dependent kidney microvascular rarefaction

    Kidney international

  2. Dapagliflozin decreases albuminuria in aged killifish.

    “reduced albuminuria”

    Animalsin aged killifishkidney

    SGLT2 Inhibition Ameliorates Age-Dependent Renovascular Rarefaction

    bioRxiv : the preprint server for biologyPreprint

More on Dapagliflozin

Blood flow restriction + resistance training

upin humans1

1 study
  1. Blood flow restriction + resistance training increases albuminuria in humans within-group post-intervention (d = −0.40).

    “In the BFR group (G4), urinary albumin levels increased significantly (p = 0.048; d = −0.40), with a moderate effect size.”

    Human trialwithin-group post-interventioncontinuous BFR at 50% diastolic blood pressureurinelow-load resistance training combined with BFR12-weekn = 10

    Effects of muscle strength training with blood flow restriction on glomerular function in people with stage 3 chronic kidney disease

    Jornal brasileiro de nefrologia

  2. Blood flow restriction + resistance training increases albuminuria in humans (stage 3 chronic kidney disease; within-group comparison).

    “Group 4 showed a significant increase in albuminuria levels (p = 0.048)”

    Human trialstage 3 chronic kidney disease; within-group comparisonlow-load3 times per week, for 30-40 minutes12 weeks

    Effects of muscle strength training with blood flow restriction on glomerular function in people with stage 3 chronic kidney disease

    Jornal brasileiro de nefrologia

More on Blood flow restriction + resistance training

Bexagliflozin

downin humans1

1 study
  1. Bexagliflozin decreases albuminuria in humans (Stage 3a/3b chronic kidney disease; compared with placebo) (20.1% reduction vs. placebo).

    “In stage 3a/3b chronic kidney disease, it reduced albuminuria by 20.1 % vs. placebo, a surrogate finding.”

    ReviewStage 3a/3b chronic kidney disease; compared with placebo

    Bexagliflozin: pharmacological profile and clinical applications of a sodium-glucose cotransporter 2 inhibitor

    Journal of basic and clinical physiology and pharmacology

More on Bexagliflozin

Finerenone + SGLT2 inhibitors

downin humans1

1 study
  1. Finerenone + SGLT2 inhibitors decrease albuminuria in humans (combination therapy in chronic kidney disease).

    “Given their complementary mechanisms and synergistic albuminuria reduction (CONFIDENCE trial)”

    Reviewcombination therapy in chronic kidney disease

    Finerenone and SGLT2 Inhibitors in Cardiorenal Disease: A Phenotype-Based Approach to Nephroprotection

    Journal of personalized medicine

More on Finerenone + SGLT2 inhibitors

Vonoprazan

downin humans1

1 study
  1. Vonoprazan decreases albuminuria in humans (Diabetic patients with kidney disease; compared with lansoprazole) (β = 19.219; 95% CI 13.62–24.817).

    “vonoprazan produced a greater reduction in albuminuria (β = 19.219; 95% IC: 13.62–24.817) and an improvement in TFGe compared with lansoprazole (p < 0.05).”

    ReviewDiabetic patients with kidney disease; compared with lansoprazolekidneyn = 140

    Long-term use of IBPs and risk of dementia and chronic kidney disease

    Contribuciones a las Ciencias Sociales

More on Vonoprazan

GLP-1 receptor agonists and multi-hormone receptor modulators

downin humans1

1 study
  1. GLP-1 receptor agonists and multi-hormone receptor modulators decrease albuminuria in humans (people without diabetes in phase-3 obesity and cardiovascular outcome trials).

    “including reductions in albuminuria and preservation of estimated glomerular filtration rate.”

    Reviewpeople without diabetes in phase-3 obesity and cardiovascular outcome trialskidney

    Glucagon-Like Peptide-1 Receptor Agonists and Multi-hormone Receptor Modulators for Kidney Protection in Nondiabetic Kidney Disease

    Journal of the American Society of Nephrology : JASN

More on GLP-1 receptor agonists and multi-hormone receptor modulators

Low-sodium diet

downin reviews1

1 study
  1. Low-sodium diet decreases albuminuria (older adults with type 2 diabetes and chronic kidney disease).

    “Sodium restriction reduced blood pressure and albuminuria”

    Reviewolder adults with type 2 diabetes and chronic kidney disease

    Dietary patterns and physical activity in relation to renal and metabolic outcomes among older adults with type 2 diabetes and chronic kidney disease: a systematic review

    Frontiers in nutrition

More on Low-sodium diet

Lixisenatide

no changein humans1

1 study
  1. Lixisenatide showed no clear effect on albuminuria in humans (type 2 diabetes and chronic kidney disease; compared with placebo).

    “Similarly, no significant changes were observed in cardio-renal risk biomarkers including albuminuria and Klotho levels.”

    Human trialtype 2 diabetes and chronic kidney disease; compared with placebo24 weeksn = 90

    Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial

    Diabetes, obesity & metabolism

More on Lixisenatide

Acetylcysteine

no changein humans1

1 study
  1. Acetylcysteine showed no clear effect on albuminuria in humans.

    “No significant changes in blood pressure, albuminuria and homocysteine plasma level were observed.”

    Human trialin non-diabetic patients with chronic kidney disease added to renin-angiotensin system blockade1200 mg/day8 weeksn = 20

    The effect of N-acetylcysteine on blood pressure and markers of cardiovascular risk in non-diabetic patients with chronic kidney disease: a placebo-controlled, randomized, cross-over study

    Medical science monitor : international medical journal of experimental and clinical research

More on Acetylcysteine

All 44

Effects

4

Cognitive function

downin humans2

2 studies
  1. Albuminuria is linked with worse cognitive function in humans (type 1 diabetes) (β −0.148, 95% CI −0.270 to −0.026).

    “sustained albumin excretion rate 30 to <300 mg/24 hours (β −0.148; 95% CI, −0.270 to −0.026)”

    Humanstype 1 diabetes32 yearsn = 1,051

    CKD Associates with Cognitive Decline in Middle-Aged and Older Adults with Long-Standing Type 1 Diabetes

    Kidney360

  2. Albuminuria is linked with worse cognitive function in humans (significantly associated with lower baseline scores and larger declines).

    “baseline UACR ≥3 mg/mmol (≥26.6 mg/g) was significantly associated with lower baseline scores and larger declines on the Modified Mini-Mental State Exam, verbal memory and processing speed tests”

    Humans≥3 mg/mmolmedian 4.7 yearsn = 18,131

    CKD Biomarkers, Cognitive Impairment, and Incident Dementia in an Older Healthy Cohort

    Kidney360

Myocardial scar

no changein humans1

1 study
  1. Albuminuria was not clearly linked with myocardial scar in humans after adjusting for CV risk factors.

    “The odds of myocardial scar were not associated with higher albumin/ACR after adjusting for CV risk factors.”

    Humansafter adjusting for CV risk factorsmyocardiumn = 2,112

    Albuminuria Linked with Interstitial Myocardial Fibrosis At The Population Level: The Multi-Ethnic Study of Atherosclerosis

    European journal of preventive cardiology

Depressive symptoms

no changein humans1

1 study
  1. Albuminuria was not clearly linked with depressive symptoms in humans (hospitalized older adults).

    “Increased albuminuria was associated with poorer cognition (p < 0.001) but showed no correlation with GDS scores.”

    Humanshospitalized older adultsn = 719

    Mental Health and Kidneys: The Interplay Between Cognitive Decline, Depression, and Kidney Dysfunction in Hospitalized Older Adults

    Journal of clinical medicine

Mild cognitive impairment

no changein humans1

1 study
  1. Albuminuria was not clearly linked with mild cognitive impairment in humans (adjusted analysis).

    “Mild cognitive impairment was associated with albuminuria on unadjusted analysis, but not with adjustment for other factors.”

    Humansadjusted analysis

    Albuminuria and dementia in the elderly: a community study

    American journal of kidney diseases : the official journal of the National Kidney Foundation

More on Mild cognitive impairment

Upstream

11

Serum uric acid

no changein humans1HR 1.19

1 study
  1. Serum uric acid was not clearly linked with albuminuria in humans (Non-obese MASLD; SUA standardised within sex) (HR 1.19, 95% CI 0.98–1.44; no clear association).

    “Albuminuria was not clearly associated (HR 1.19, 95% CI 0.98–1.44).”

    HumansNon-obese MASLD; SUA standardised within sex

    Serum Uric Acid Identifies a Kidney Filtration–Risk Phenotype in Diabetes-Enriched Non-Obese Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicentre Cohort Study

    Research SquarePreprint

More on Serum uric acid

ESRRG

downin mice1

1 study
  1. ESRRG protects against albuminuria in mice (podocyte-specific ERRγ deletion).

    “when the mice were aged to 21 months of age, there was a significant increase in albuminuria and decrease in podocyte density.”

    Animalspodocyte-specific ERRγ deletionkidney

    ERRγ deletion in podocytes accelerates aging related kidney disease

    bioRxiv : the preprint server for biologyPreprint

More on ESRRG

AMPK signaling

downin mice1

1 study
  1. AMPK signaling prevents albuminuria in mice under diabetic conditions, shown by podocyte knockout of AMPK α1 and α2.

    “They also showed more significant albuminuria compared to control diabetic mice.”

    Animalsunder diabetic conditions, shown by podocyte knockout of AMPK α1 and α2kidney

    AMPK is dispensable for physiological podocyte and glomerular functions but prevents glomerular fibrosis in experimental diabetes

    Cell death discovery

More on AMPK signaling

PRAT thickness

no changein humans1

1 study
  1. PRAT thickness was not clearly linked with albuminuria in humans (post-donation).

    “There was no association of PRAT and PFS with post-donation albuminuria.”

    Humanspost-donation

    Perirenal Adipose Tissue may be an Important Predictor of Adverse Kidney Outcomes in Living Kidney Donors

    Kidney international reports

More on PRAT thickness

Time

downin humans1OR 0.93

1 study
  1. time is linked with lower albuminuria in humans among individuals with diabetes (OR 0.93, 95% CI 0.88-0.98).

    “∼7% per 4-year period (OR=0.93, 95% CI=0.88, 0.98) for albuminuria”

    Humansamong individuals with diabetes4-year periodn = 7,320

    Decreasing Prevalence of Chronic Kidney Disease Among U.S. Adults With Diabetes, 1999-2018

    AJPM focus

Age

upin humans1

1 study
  1. Age is linked with higher albuminuria in humans (type 2 diabetes with diabetic kidney disease).

    “a more pronounced rise in albuminuria was evident in the ⩾75 years group during the first to the second year.”

    Humanstype 2 diabetes with diabetic kidney diseasefirst to the second yearn = 304

    Age-related markers and predictors of diabetic kidney disease progression in type 2 diabetes patients: a retrospective cohort study

    Therapeutic advances in endocrinology and metabolism

More on Age

Thyroid hormones

no changein humans1

1 study
  1. Thyroid hormones were not clearly linked with albuminuria in humans.

    “No significant associations between thyroid hormone levels and albuminuria were found”

    Humans

    High Thyroid-Stimulating Hormone and Low Free Triiodothyronine Levels Are Associated with Chronic Kidney Disease in Three Population-Based Studies from Germany

    Journal of clinical medicine

More on Thyroid hormones

ACE2

downin rats1

1 study
  1. ACE2 decreases albuminuria in rats (ageing).

    “severe albuminuria which was significantly less pronounced in TGR(SM22hACE2) rats”

    Animalsageingkidney

    Transgenic angiotensin-converting enzyme 2 overexpression in the rat vasculature protects kidneys from ageing-induced injury

    Kidney international

More on ACE2

TRPC6

no changein rats1

1 study
  1. TRPC6 showed no clear effect on albuminuria in rats (shown by CRISPR-Cas9 deletion; changes at 12 months of age).

    “These changes were equally severe in Trpc6wt/wt and Trpc6del/del rats.”

    Animalsshown by CRISPR-Cas9 deletion; changes at 12 months of age

    Effects of TRPC6 Inactivation on Glomerulosclerosis and Renal Fibrosis in Aging Rats

    Cells

More on TRPC6

HMOX1

upin rats1

1 study
  1. HMOX1 increases albuminuria in rats (podocyte-targeted overexpression, compared with age-matched wild-type rats) (significantly higher than age-matched WT controls at 12 months).

    “GECHO-1 rats older than 6 months developed albuminuria that was detectable at 6 months and became significantly higher compared to age-matched WT controls at 12 months.”

    Animalspodocyte-targeted overexpression, compared with age-matched wild-type ratskidney12 months

    Podocyte-targeted Heme Oxygenase (HO)-1 overexpression exacerbates age-related pathology in the rat kidney

    Scientific reports

More on HMOX1

All 11

Associations

55

Mortality

upin humans6HR 1.742–1.87

6 studies
  1. Albuminuria is associated with mortality in humans (community-dwelling) (HR 1.87, 95% CI 1.75-2.00).

    “Macroalbuminuria (HR 1.87, 95% CI 1.75-2.00) and eGFR < 30 mL/min/1.73 m2 (HR 1.91, 95% CI 1.79-2.04) were independently associated with mortality.”

    Humanscommunity-dwelling40-month

    Implementation of KDIGO CKD Screening and Its Prognostic Implications in Community-Dwelling Adults Aged 75 Years or Older: A Population-Based Cohort Study

    Journal of clinical medicine

  2. Albuminuria predicts mortality in humans (adjusted for covariates including coronary artery calcium).

    “Albuminuria and UACR each improve total mortality prediction as well.”

    Humansadjusted for covariates including coronary artery calciumn = 6,707

    Impact of Renal Disease Markers on Cardiovascular Disease Risk Prediction When Coronary Calcium Score Is Known

    Journal of the American Heart Association

  3. Albuminuria is linked with a higher risk of mortality in humans (type 2 diabetes) (HR 1.742 (1.411-2.153) for A2, 1.810 (1.344-2.441) for A3).

    “The HRs of all-cause mortality were 1.742 (1.411-2.153) for A2 and 1.810 (1.344-2.441) for A3.”

    Humanstype 2 diabetesn = 3,065

    Prognostic significance of albuminuria in elderly of various ages with diabetes

    Scientific reports

  4. Albuminuria predicts mortality in humans.

    “The amount of albumin excreted in the urine is an independent predictor of declining kidney function, cardiovascular events, and all-cause mortality.”

    Review

    Albuminuria for detection of chronic kidney disease: biomarker and therapeutic target

    Orvosi hetilap

  5. Albuminuria predicts mortality in humans across estimated glomerular filtration rate strata.

    “Albuminuria predicts mortality, CKD progression, and HF events across estimated Glomerular Filtration Rate (eGFR) strata”

    Reviewacross estimated glomerular filtration rate strata

    Clinical Importance of Albuminuria Reduction in Multimorbid Older Adults with Cardiovascular Disease: SGLT2 Inhibitor Therapy and Implications for Polypharmacy

    Current vascular pharmacology

  6. Albuminuria predicts mortality in humans (chronic kidney disease).

    “Albuminuria is a key biomarker in predicting the risk of death and progression to ESKD.”

    Reviewchronic kidney disease

    OLDER PEOPLE WITH CHRONIC KIDNEY DISEASE: DEFINITION, AND INFLUENCE OF BIOMARKERS AND MEDICATIONS UPON CARDIOVASCULAR AND RENAL OUTCOMES

    Journal of renal care

Heart failure

upin humans3HR 1.24–1.33

3 studies
  1. Albuminuria is associated with heart failure in humans (Treated hypertensive patients; albuminuria severity categories) (HR 1.24 for ±, p=0.03; HR 1.26 for +/++/+++, p<0.01).

    “albuminuria conferred incrementally greater risk across severity categories”

    HumansTreated hypertensive patients; albuminuria severity categories

    Low Diastolic Blood Pressure and Cardiometabolic Burden Predict Heart Failure in Treated Hypertensive Patients: Insights From the Korean Hypertension Cohort

    International journal of heart failure

  2. Albuminuria predicts heart failure in humans (adjusted for covariates including coronary artery calcium) (P<0.001).

    “Albuminuria significantly increased disease prediction for heart failure and for total mortality (P<0.001) but not for other outcomes.”

    Humansadjusted for covariates including coronary artery calciumn = 6,707

    Impact of Renal Disease Markers on Cardiovascular Disease Risk Prediction When Coronary Calcium Score Is Known

    Journal of the American Heart Association

  3. Albuminuria is linked with a higher risk of heart failure in humans (HR 1.33 (95% CI, 1.05 to 1.70)).

    “Participants with albuminuria (UACR ≥3.0 mg/mmol; 11.3%) had higher risk for HHF, HF death and the combined HF outcome compared with those with no albuminuria (HRs 1.47 (95% CI 1.12 to 1.92), 1.55 (95% CI 1.04 to 2.33) and 1.33 (95% CI, 1.05 to 1.70), respectively).”

    Humansmedian follow-up of 8.6 yearsn = 17,834

    Kidney function and risk of heart failure in older adults: findings from a prospective cohort study

    Heart (British Cardiac Society)

More on Heart failure

Cognitive function

downin humans3

3 studies
  1. Albuminuria is associated with cognitive function in humans.

    “The poorer cognitive performance was linked to higher albuminuria, especially in the processing speed and executive ability.”

    Humans

    Psychological and Neurocognitive Dimensions of Kidney Disease: Mental Health Impacts of Chronic Hypertension and Systemic Illness

    KIDNEYS

  2. Albuminuria is associated with cognitive function in humans (independent of CVD risk factors).

    “More albuminuria was associated with lower cognitive function, cognitive decline, independent of CVD risk factors.”

    Humansindependent of CVD risk factorsn = 6,377

    Kidney function and cognitive aging and impairment among diverse Hispanic/Latino individuals: Study of Latinos-Investigation of Neurocognitive Aging (HCHS/SOL)

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  3. Albuminuria is associated with cognitive function in humans (frail older adults with hypertension, prediabetes, and CKD) (r: 0.8846, p < 0.0001).

    “We examined the association between albuminuria and MoCA Score, revealing a significant inverse correlation (r: 0.8846; p < 0.0001).”

    Humansfrail older adults with hypertension, prediabetes, and CKDthree monthsn = 237

    Frail hypertensive older adults with prediabetes and chronic kidney disease: insights on organ damage and cognitive performance - preliminary results from the CARYATID study

    Cardiovascular diabetology

SGLT2 inhibitors

downin humans2−40% albuminuria

2 studies
  1. SGLT2 inhibitors are associated with albuminuria in humans (multivariable logistic regression) (aOR 0.54, 95% CI 0.30-0.95).

    “SGLT2 inhibitor therapy was associated with lower odds of albuminuria (aOR 0.54, 95% CI 0.30-0.95)”

    Humansmultivariable logistic regression

    Real-World Pharmacological Patterns and Residual Cardiometabolic Risk in Patients with Type 2 Diabetes in Romania

    Diseases (Basel, Switzerland)

  2. SGLT2 inhibitors are associated with albuminuria in humans (type 1 diabetes) (Up to 40% reduction in albuminuria).

    “SGLT2i has been associated with up to 40% reduction in albuminuria and attenuation of the estimated glomerular filtration rate (eGFR) decline.”

    Reviewtype 1 diabetes

    SGLT2 Inhibitors in Type 1 Diabetes Mellitus: The Kidney and Heart Perspective

    Handbook of experimental pharmacology

More on SGLT2 inhibitors

Cardiovascular disease

upin humans2HR 1.61

2 studies
  1. Albuminuria is associated with cardiovascular disease in humans (HR 1.61, 95% CI 1.30-1.98).

    “albuminuria (HR, 1.61 [95% CI, 1.30-1.98])”

    Humans5 yearsn = 2,450

    Cardiovascular Events in US Adults Aged ≥80 Years: Incidence, Risk Factors, and Outcomes

    Circulation. Population health and outcomes

  2. Albuminuria is associated with cardiovascular disease in humans (cardiovascular-kidney-metabolic syndrome).

    “Albuminuria, alongside eGFR, plays a central role not only as a marker of kidney damage but as an independent cardiovascular risk factor.”

    Reviewcardiovascular-kidney-metabolic syndrome

    Innovative holistic treatment for CKM: what lies ahead?

    European journal of internal medicine

More on Cardiovascular disease

Major osteoporotic fractures

upin humans2

2 studies
  1. Albuminuria is associated with major osteoporotic fractures in humans (independent of eGFR, compared with A1).

    “Albuminuria (A2/A3) was associated with both lower bone mineral density and slightly higher fracture risk compared with A1, independent of eGFR.”

    Humansindependent of eGFR, compared with A1

    Kidney Function and Albuminuria Associated with Bone Mineral Density and Fracture Risk: The Tromsø and Trøndelag Health Studies

    Kidney360

  2. Albuminuria is associated with major osteoporotic fractures in humans (Type 2 diabetes; stratified by obesity status) (Obese: aHR 1.13, 95% CI 1.01–1.26; non-obese: aHR 1.28, 95% CI 1.15–1.43).

    “albuminuria emerged as an important predictor of fracture risk.”

    HumansType 2 diabetes; stratified by obesity statusMedian follow-up of 5.3 years54.2% mensn = 165,289

    Associations of Albuminuria and Metabolic Syndrome Traits With Fracture Risk in Patients With Type 2 Diabetes: A Population-Based Cohort Study

    Journal of cachexia, sarcopenia and muscle

More on Major osteoporotic fractures

Chronic kidney disease

upin humans2+6.8%

2 studies
  1. Albuminuria predicts chronic kidney disease in humans (aOR 33.39, 95% CI 10.41-107.13).

    “A2-A3 albuminuria strongly predicted CKD (aOR 33.39, 95% CI 10.41-107.13)”

    Humans

    Sex, menopause and chronic kidney disease in primary care

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

  2. Albuminuria is associated with chronic kidney disease in humans (6.8%).

    “Most importantly, 6.8% of all subjects and 3.2% of subjects without hypertension, diabetes or known kidney disease had chronic increased albuminuria, consistent with the presence of CKD.”

    Humans5 yearsn = 9,331

    Increased albuminuria is highly prevalent in the general population: prevalence of CKD in the Gutenberg Health Study

    Clinical kidney journal

More on Chronic kidney disease

Hip fracture

upin humans2OR 1.37

2 studies
  1. Albuminuria is associated with hip fracture in humans (Type 2 diabetes; stratified by obesity status) (Obese: aHR 1.33, 95% CI 1.11–1.60; non-obese: aHR 1.54, 95% CI 1.33–1.78).

    “Albuminuria was the strongest risk factor for hip fractures (obese: aHR 1.33, 95% CI 1.11-1.60; non-obese: 1.54, 1.33-1.78)”

    HumansType 2 diabetes; stratified by obesity statusMedian follow-up of 5.3 years54.2% mensn = 165,289

    Associations of Albuminuria and Metabolic Syndrome Traits With Fracture Risk in Patients With Type 2 Diabetes: A Population-Based Cohort Study

    Journal of cachexia, sarcopenia and muscle

  2. Albuminuria is associated with hip fracture in humans (severe versus none/mild albuminuria; multivariable analysis controlled for 42 variables) (OR 1.37, 95% CI 1.28–1.47).

    “Patients with severe albuminuria had an increased risk of hip fracture (odds ratio [OR] = 1.37; 95% confidence interval [CI] 1.28, 1.47])”

    Humanssevere versus none/mild albuminuria; multivariable analysis controlled for 42 variables

    Degree of Albuminuria is Associated With Increased Risk of Fragility Fractures Independent of Estimated GFR

    Kidney international reports

More on Hip fracture

Frailty

upin humans2OR 1.12

2 studies
  1. Albuminuria is associated with frailty in humans (OR 1.12, 95% CI 1.05–1.25, p = 0.001).

    “The odds ratio of ACR was 1.12 (95% confidence interval 1.05–1.25, p = 0.001) with adjustments for age, body mass index, estimated glomerular filtration rate, diabetes, liver function, and cholesterol.”

    Humansadjusted for age, body mass index, estimated glomerular filtration rate, diabetes, liver function, and cholesteroln = 1,347

    Association between frailty and albuminuria in the community-dwelling geriatric population: Taichung Community Health Study for Elders

    Research SquarePreprint

  2. Albuminuria is associated with frailty in humans (multivariable analysis).

    “or categorical variable (OR 1.21 [1.08-1.36]; p = .001) was consistently associated with prefrailty-frailty.”

    Humansmultivariable analysisn = 17,759

    The association of frailty with chronic kidney disease in older adults using the ASPirin in reducing events in the elderly cohort

    Nephrology (Carlton, Vic.)

Dementia

upin humans2HR 1.32

2 studies
  1. Albuminuria is linked with a higher risk of dementia in humans (HR 1.32, 95% CI 1.06 to 1.66).

    “and dementia (HR, 1.32; 95% CI, 1.06 to 1.66).”

    Humans≥3 mg/mmolmedian 4.7 yearsn = 18,131

    CKD Biomarkers, Cognitive Impairment, and Incident Dementia in an Older Healthy Cohort

    Kidney360

  2. Albuminuria is associated with dementia in humans (multivariable adjusted) (OR 1.12, 95% CI 1.03 to 1.22).

    “Adjustment for prevalent cardiovascular disease and cardiovascular risk factors, lipid levels, C-reactive protein level, estimated glomerular filtration rate, and apolipoprotein E-4 genotype attenuated this association, but it remained statistically significant (OR, 1.12; 95% CI, 1.03 to 1.22).”

    Humansmultivariable adjusted

    Albuminuria and dementia in the elderly: a community study

    American journal of kidney diseases : the official journal of the National Kidney Foundation

More on Dementia

All 55

Funding

3 grants since 2019

Japan Society for the Promotion of Science¥4.2MInstituto de Salud Carlos III€201KEuropean and Developing Countries Clinical Trials Partnership€148K

Latest

Dec 2025: 9Jan 2026: 37Feb 2026: 45Mar 2026: 40Apr 2026: 6May 2026: 6Jun 2026: 14Jul 2026: 15Aug 2026: 36Sep 2026: 32Oct 2026: 66Nov 2026: 51357 papers in 12 months
European Heart Journal Open

Chronic kidney disease linked to higher stroke risk

Hazard ratios, measures of relative risk, were 1.61 for stroke and 1.89 for early-onset stroke with chronic kidney disease versus without it.Hazard ratios, measures of relative risk, were 1.61 for stroke and 1.89 for early-onset stroke with chronic kidney disease versus without it.

Cohort · 381,886 peopleChronic kidney disease

See all 666 papers on albuminuria